Pfizer Beats Q1 2026 Estimates, Reaffirms Full-Year Guidance
Pfizer (PFE) reported Q1 2026 revenue and adjusted profit above analyst estimates, driven by growth in launched and acquired products. The drugmaker reaffirmed its full-year financial outlook.
Key Numbers
Pfizer Inc (NYSE: PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as the drugmaker reaffirmed its full-year financial outlook.
Key Financial Results
| Metric | Q1 2026 | Consensus Estimate | YoY Change |
|---|---|---|---|
| Revenue | $12.5B | $11.8B | +8% |
| Adjusted EPS | $2.45 | $2.30 | +12% |
| Net Income | $4.2B | - | +10% |
Highlights from the Report
Pfizer attributed the strong performance to growth in new products such as its RSV vaccine and cancer drug Padcev, as well as contributions from acquired products via the Seagen deal. Cost-cutting measures also improved margins.
Future Guidance
The company reaffirmed its full-year 2026 guidance: revenue between $48B and $50B, and adjusted EPS between $8.50 and $9.00.
Stock Reaction
Pfizer shares rose 2.5% in pre-market trading following the announcement, reflecting investor optimism over the beat and reaffirmed guidance.
What This Means for Investors
The earnings beat and reaffirmed guidance boost confidence in Pfizer's growth trajectory despite industry headwinds. However, attention remains on new product performance and the ability to offset declining COVID vaccine revenue.
Frequently Asked Questions
Found this useful? Share it